Section 3(D)

Germany’s Boehringer Repudiated Patent on HIV Drug- Nevirapine

24th December, 2015 - 1:39 pm Categories: India News & Updates Patents pharma Section 3(D)

The Indian Patent Office has repudiated Germany’s Boehringer Ingelheim patent on its key HIV drug- Nevirapine, Patent Application Number: 4724/DELNP/2009 entitled “Extended release formulation of Nevirapine”, for a version sold as Viramune XR (extended release), once again forestalling attempts by Big Pharma for “exclusivity” extension on their patented drugs to reportedly block entry of reasonably … Continue reading Germany’s Boehringer Repudiated Patent on HIV Drug- Nevirapine

Revocation of Valganciclovir patent by Controller of Patents, Chennai

1st August, 2015 - 9:46 am Categories: IPAB IPAB Decisions News & Updates Patent Opposition Patents pharma Pharma/Biotech Patent Litigations Section 3(D)

0 Comments

Recently in a matter remanded from IPAB to Controller of Patents, Chennai, a decision of revoking Roche’s patent IN207232 for Valganciclovir was delivered after hearing both the parties. The subject patent was granted on January, 2009 followed which post grant oppositions were separately filed by CIPLA, Matrix, Ranbaxy and Bakul Pharma along with two NGOs … Continue reading Revocation of Valganciclovir patent by Controller of Patents, Chennai

Section 3(D) of Indian Patent Act Strikes Again

27th July, 2015 - 5:24 am Categories: India News & Updates patent infringement Patent Opposition Patents pharma Section 3(D)

0 Comments

India revoked yet another drug patent granted to a German MNC, Boehringer Ingelheim, for its respiratory drug, Spiriva (crystalline tiotropium bromide monohydrate) at a time when the US is putting pressure on the Indian government for not providing adequate patent protection to multinational drug companies. In its decision, the patent office held that Boehringer failed … Continue reading Section 3(D) of Indian Patent Act Strikes Again

Recent decision of Delhi High Court in the case of GILEAD PHARMASSET, LLC V. UNION OF INDIA & ANR

23rd February, 2015 - 7:46 am Categories: IP Practice in India News & Updates Patents pharma Section 3(D)

0 Comments

Recently, the Delhi high court on dated 30th January 2015 set aside an order of the Deputy Controller of Patents and Designs. The impugned order rejected a patent to US drug maker Gilead for its hepatitis C drug “Sovaldi” on dated 13th January 2015. Facts of the case: M/S GILEAD PHARMASSET, INC, USA, filed a … Continue reading Recent decision of Delhi High Court in the case of GILEAD PHARMASSET, LLC V. UNION OF INDIA & ANR

Category: Section 3(D)

Germany’s Boehringer Repudiated Patent on HIV Drug- Nevirapine

Revocation of Valganciclovir patent by Controller of Patents, Chennai

Section 3(D) of Indian Patent Act Strikes Again

Recent decision of Delhi High Court in the case of GILEAD PHARMASSET, LLC V. UNION OF INDIA & ANR

Categories

Archives